Valuation: Chugai Pharmaceutical Co., Ltd.

Capitalization 12,845B 81.37B 69.49B 63.67B 60.19B 111B 7,788B 112B 758B 295B 3,696B 305B 299B P/E ratio 2026 *
25.2x
P/E ratio 2027 * 21.8x
Enterprise value 11,875B 75.22B 64.24B 58.86B 55.65B 103B 7,199B 104B 701B 273B 3,416B 282B 276B EV / Sales 2026 *
8.59x
EV / Sales 2027 * 7.64x
Free-Float
38.12%
Yield 2026 *
1.75%
Yield 2027 * 1.98%
1 day+3.73%
1 week+0.01%
Current month-0.25%
1 month-4.98%
3 months-12.78%
6 months-0.21%
Current year-1.78%
1 week 7,691
Extreme 7691
8,248
1 month 7,402
Extreme 7402
9,013
Current year 7,402
Extreme 7402
10,700
1 year 5,942
Extreme 5942
10,700
3 years 3,580
Extreme 3580
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2021
Director of Finance/CFO - 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 01/03/1993
Director/Board Member 81 01/03/2015
Director/Board Member 77 01/03/2017
Change 5d. change 1-year change 3-years change Capi.($)
+3.73%+0.01%+7.95%+124.08% 81.37B
+2.61%+2.91%+36.15%+133.81% 906B
+2.75%+2.58%+55.23%+43.31% 555B
+0.31%+1.69%+10.90%+41.69% 368B
-0.94%-2.05%+21.74%+10.73% 326B
+0.59%+4.06%+38.24%+15.45% 289B
+0.78%+1.00%+29.63%+26.23% 285B
+0.96%-0.10%+48.05%-3.15% 280B
+0.91%+2.12%-31.78%-49.10% 208B
+0.05%+1.61%+24.40%+44.43% 182B
Average +0.63%+0.44%+24.05%+38.75% 347.98B
Weighted average by Cap. +0.37%+1.09%+30.43%+52.62%

Financials

2026 *2027 *
Net sales 1,382B 8.76B 7.48B 6.85B 6.48B 11.99B 838B 12.06B 81.58B 31.76B 398B 32.85B 32.16B 1,521B 9.64B 8.23B 7.54B 7.13B 13.2B 922B 13.27B 89.79B 34.96B 438B 36.16B 35.4B
Net income 511B 3.23B 2.76B 2.53B 2.39B 4.43B 310B 4.45B 30.13B 11.73B 147B 12.13B 11.88B 589B 3.73B 3.19B 2.92B 2.76B 5.11B 357B 5.14B 34.75B 13.53B 169B 13.99B 13.7B
Net Debt -970B -6.15B -5.25B -4.81B -4.55B -8.42B -588B -8.46B -57.27B -22.29B -279B -23.06B -22.58B -1,226B -7.77B -6.63B -6.08B -5.75B -10.64B -743B -10.7B -72.37B -28.18B -353B -29.15B -28.54B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
14/05/26 8,096.00 ¥ +3.73% 2,811,500
13/05/26 7,805.00 ¥ +0.14% 2,385,200
12/05/26 7,794.00 ¥ -2.00% 2,123,700
11/05/26 7,953.00 ¥ +0.67% 3,038,800
08/05/26 7,900.00 ¥ -2.41% 4,228,200
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,805.00JPY
Average target price
10,096.67JPY
Spread / Average Target
+29.36%

Quarterly revenue - Rate of surprise